A Case of Successful Treatment with an Immune Checkpoint Inhibitor after Head and Neck Photoimmunotherapy.

ABSTRACT:

Introduction

Head and neck photoimmunotherapy (HN-PIT) has been conditionally approved by the Japanese government for the treatment of unresectable locally advanced or locally recurrent head and neck cancer since January 2021. HN-PIT makes local treatment of locally recurrent disease possible in cases where systemic drug therapy would have previously been the only option. However, when treatment is ineffective and the disease progresses, it is necessary to shift to conventional drug therapies. We report a case in which an immune checkpoint inhibitor (ICI) was successfully administered to a patient with advanced disease following HN-PIT.

Case presentation

A 75-year-old male patient presented with local recurrence of mandibular gingival cancer. The primary treatment consisted

SUBMITTER: Hanyu K 

PROVIDER: S-EPMC10827299 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature